Bioscience industry stakeholder collaboration key to addressing inequality

When a global pandemic hit, the bioscience industry answered the call for vaccines and therapies in record time, which will save millions of lives. This response was possible because of a sustained investment of risk-capital by the venture capital industry in life sciences companies, peaking in 2020. Great scientists, visionary leadership and high-quality investors that backed new science and bold entrepreneurs led to the innovative technologies of BioNTech and Moderna that contributed to the initial Covid-19 vaccines.

As the sector rightly basks in the glow of this year’s accomplishments, there is a concurrent reality to confront. Covid-19 has further exposed the inequities in society, disproportionately impacting women and minorities. This imbalance is also evident in the bioscience community, provoking many leaders to act on inequality.